Dietary supplements are increasingly popular in the U.S., but they can pose risks, particularly regarding interactions with prescription medications. Cardiologist Dr. Anum Minhas emphasizes the importance of consulting with healthcare providers before starting any new supplement…
A new federal rule proposed by Health and Human Services Secretary Robert F. Kennedy Jr. seeks to enhance oversight of food additives by closing the GRAS loophole. This rule would…
The FDA is contemplating regulatory changes for unregulated peptides, which are popular in fitness and wellness communities but lack thorough safety testing. Experts express conce…
Recent clinical trials indicate that synthetic 5-MeO-DMT, a psychedelic compound derived from the Sonoran Desert toad, may offer significant antidepressant effects for treatment-r…
An FDA advisory committee has voted to recommend broader access to six peptides, potentially allowing licensed compounding pharmacies to prepare them for valid prescriptions. This…
The FDA has approved Awiqli, a once-weekly long-acting basal insulin injection for adults with type 2 diabetes. This innovative treatment offers a convenient alternative to daily…
The FDA is reviewing seven unapproved peptides that have gained popularity for their purported health benefits, including weight loss and chronic disease management. The review co…
The FDA has granted approval for Lipfendra, the first oral PCSK9 inhibitor designed to treat high cholesterol, particularly familial hypercholesterolemia. This new medication offe…
The FDA has granted priority review to Lipfendra, the first oral medication designed to block the PCSK9 protein, which is crucial in regulating LDL cholesterol levels. This develo…
The FDA has approved Lipfendra, a groundbreaking pill from Merck designed to significantly lower cholesterol levels in patients at high risk of heart disease. This noninjectable m…
The FDA has approved Lipfendra, the first once-daily oral PCSK9 inhibitor, which can reduce LDL cholesterol levels by 56% to 60% when used alongside statins. Developed by Merck, t…
The FDA has approved setmelanotide, a new treatment for acquired hypothalamic obesity, following the results of the Phase 3 TRANSCEND clinical trial. This condition, often affecti…
In an ambitious move, RFK Jr. aims to ease access to unapproved peptide drugs, assuring patients they’ll receive a 'more controlled alternative' while keeping the actual safety of…
Anavex Life Sciences is making strides in its Phase 3 planning for Alzheimer's disease with the FDA, having submitted clinical trial data and reporting a cash position of $118.3 m…